People: BioDelivery Sciences International Inc (BDSI.PH)

Summary

Name	Age	Since	Current Position
Francis O'Donnell	63	2012	Executive Chairman of the Board
Mark Sirgo	59	2006	President, Chief Executive Officer, Director
James McNulty	62	2008	Chief Financial Officer, Treasurer, Secretary
Andrew Finn	63	2007	Executive Vice President - Product Development
William Stone	69	2007	Lead Independent Director
Thomas D'Alonzo	66	2013	Director
William Poole	66	2005	Independent Director
Samuel Sears	69	2011	Independent Director
John Shea	86	2002	Independent Director
Brian Korb			IR Contact Officer

» Insider Trading

Biographies

Name	Description
Francis O'Donnell	Dr. Francis E. O'Donnell, Jr., M.D., is Executive Chairman of the Board of BioDelivery Sciences International Inc. For more than the last six years, Dr. O’Donnell has served as Manager of The Hopkins Capital Group, an affiliation of limited liability companies which engage in private equity and venture capital investing in disruptive technologies in healthcare. He serves as Executive Chairman of Accentia. Dr. O’Donnell is a graduate of The Johns Hopkins School of Medicine and received his residency training at the Wilmer Ophthalmological Institute, Johns Hopkins Hospital. Dr. O’Donnell is a former professor and Chairman of the Department of Ophthalmology, St. Louis University School of Medicine. He is a trustee of St. Louis University.
Mark Sirgo	Dr. Mark A. Sirgo, Pharm.D., is President, Chief Executive Officer and Director of BioDelivery Sciences International Inc. Dr. Sirgo has nearly 30 years of experience in the pharmaceutical industry, including 16 years in clinical drug development, 7 years in marketing, sales, and business development and 8 years in executive management positions. Prior to his involvement with Arius Pharmaceuticals from 2003 to 2004, he spent 16 years in a variety of positions of increasing responsibility in both clinical development and marketing at Glaxo, Glaxo Wellcome, and GlaxoSmithKline, including Vice President of International OTC Development and Vice President of New Product Marketing. Dr. Sirgo was responsible for managing the development and FDA approval of Zantac 75 while at Glaxo Wellcome, among other accomplishments. From 1996 to 1999, Dr. Sirgo was Senior Vice President of Global Sales and Marketing at Pharmaceutical Product Development, Inc. (NASDAQ:PPDI), a contract service provider to the pharmaceutical industry. Dr. Sirgo serves on the board of directors and as Chairman of the Compensation Committee of Salix Pharmaceuticals, Inc. (NASDAQ:SLXP), a specialty pharmaceutical company specializing in gastrointestinal products since 2008. Dr. Sirgo is qualified to serve on board of directors because of his experience in specialty biopharmaceutical companies. Dr. Sirgo received his BS in Pharmacy from The Ohio State University and his Doctorate from Philadelphia College of Pharmacy and Science.
James McNulty	Mr. James A. McNulty, CPA, is Secretary, Treasurer and Chief Financial Officer of BioDelivery Sciences International Inc. Since 2000, Mr. McNulty has also served as Chief Financial Officer of Hopkins Capital Group, an affiliation of limited liability companies which engage in venture investing activities. Hopkins Capital Group is owned and controlled by Dr. Frank E. O’Donnell, Jr. Mr. McNulty also serves part-time as the Treasurer and Corporate Secretary of Accentia, a holding company with commercialization assets in specialty pharmaceuticals and biologics, and from 2003 to 2007 as Chief Financial Officer for Biovest, a majority-owned subsidiary of Accentia. He served as CFO of Star Scientific, Inc. from 1998 - 2000. During 2000 - 2002 he served as CFO/COO of American Prescription Providers, Inc. Mr. McNulty has performed accounting and consulting services as a Certified Public Accountant since 1975. He co-founded Pender McNulty & Newkirk, which became one of Florida’s regional CPA firms, and was a founder/principal in two other CPA firms, McNulty & Company, and McNulty Garcia & Ortiz. He is a Director of Quantum Technology Sciences, Inc., a private company. He is a published co-author (with Pat Summerall) of Business Golf, the Art of Building Relationships on the Links. Mr. McNulty is qualified to serve on management team because of his experience in public and private accounting. Mr. McNulty is a graduate of University of South Florida, a licensed Certified Public Accountant, a member of the American and Florida Institutes of CPA’s and is a board member of the Tampa Bay chapter of Financial Executives International.
Andrew Finn	Dr. Andrew L. Finn, Pharm.D., is Executive Vice President - Product Development of BioDelivery Sciences International Inc. Dr. Finn has nearly 30 years experience in pharmaceutical product development. Prior to his involvement with Arius, he was, from 2000 to 2003, Executive Vice President of Product Development at POZEN Inc. with responsibilities for formulation development, non-clinical development, clinical research and regulatory affairs. He participated in the POZEN activities up to the initial public offering and submitted marketing applications in Europe and the U.S. for two migraine products. From 1996 to 1999, Dr. Finn was Co-Founder and Chief Executive Officer of enVision Sciences, a regulatory and clinical service company. From 1991 to 1996, he was Vice President of Clinical Research and Biometrics for Solvay Pharmaceuticals, where he oversaw NDA submissions in the areas of inflammatory bowel disease, osteoporosis prevention and treatment of obsessive-compulsive disorder. Prior to this, he spent 10 years in positions of increasing responsibility at Glaxo Inc., where he oversaw a number of NDA submissions, including Zofran for chemotherapy induced nausea and vomiting. Dr. Finn received his BS in Pharmacy from the University of North Carolina and his Doctorate from the University of Michigan.
William Stone	Mr. William B. Stone is Lead Independent Director of BioDelivery Sciences International Inc. For thirty years, until his retirement in October 2000, Mr. Stone was employed with Mallinckrodt Inc. For the last twenty years of his career, he held positions of Vice President and Corporate Controller and Vice President and Chief Information Officer for 16 years and 4 years, respectively. During his tenure at Mallinckrodt, Mr. Stone was responsible for global accounting and reporting, financial organization, staffing and development, and systems of internal accounting control. In this capacity, he was responsible for Mallinckrodt’s SEC and other financial filings, internal management performance reports, strategic and tactical financial planning and for evaluation of capital sources and investments. Mr. Stone presented financial analyses and special projects to Mallinckrodt’s board of directors and audit committee, and reported to the audit committee regarding the conduct and effectiveness of the independent accountant’s quarterly reviews and annual audit. In the capacity of Chief Information Officer, Mr. Stone was responsible for Mallinckrodt’s worldwide computer information systems and organization, staffing and development. He assessed effectiveness and control for computer-assisted information systems and led a program for justification, selection and deployment of global standardized computer hardware and software. Further, Mr. Stone reported to the audit committee as leader of Mallinckrodt’s global program to address Year 2000 implications associated with computer-assisted information, laboratory control and process control computer hardware and software. Mr. Stone is a graduate of the University of Missouri-Columbia where he earned BS and MA degrees in accounting, and is a Certified Public Accountant.
Thomas D'Alonzo	Mr. Thomas W. D'Alonzo has been appointed as Director of BioDelivery Sciences International, Inc., effective April 23, 2013. Prior to joining the company, Mr. D’Alonzo served as a member of the board of directors of Salix Pharmaceuticals, Ltd. since May 2000 and has been the Chairman of the Board since June 2010. From 2005 to 2012, Mr. D’Alonzo served on the board of directors of Amarillo Biosciences, Inc., a public company, and Plexigen, Inc., a private company. From March 2007 to February 2009, Mr. D’Alonzo served as the Chief Executive Officer and a director of MiMedx Group, Inc. From May 2006 to April 2007, Mr. D’Alonzo was Chief Executive Officer of DARA BioSciences, Inc., now known as DARA Pharmaceuticals, Inc., and he served on its board of directors from September 2005 to December 2008. From 2006 to 2008, he also served on company's board of directors. From 2000 to 2007, Mr. D’Alonzo acted as an independent consultant. Prior to that, from 1996 to 1999, Mr. D’Alonzo served as President and Chief Operating Officer of Pharmaceutical Product Development (PPD), a global provider of discovery and development services to pharmaceutical and biotechnology companies. Before joining PPD, from 1993 to 1996, he served as President and Chief Executive Officer of GenVec, Inc., a clinical-stage, biopharmaceutical company. From 1983 to 1993, Mr. D’Alonzo held positions of increasing responsibility within Glaxo, Inc., the U.S. division of GSK, including President. Mr. D’Alonzo received his B.S. in Business Administration from the University of Delaware, and his J.D. from the University of Denver College of Law.
William Poole	Mr. William S. Poole is Independent Director of BioDelivery Sciences International Inc. He has experience in the biopharmaceutical and medical device industries for over thirty years. From 1972 to early 1996, Mr. Poole worked for Lederle Laboratories, a Division of American Cyanamid Company. During his 24-year career at Cyanamid, Mr. Poole held positions of increasing responsibility and held the position of World-Wide Division President of the Medical Device Division when Wyeth acquired Cyanamid in 1995. He later served as President, North American Pharmaceuticals, of Novo Nordisk Pharmaceuticals, and also as President of Biovail Pharmaceuticals. In both of these companies, Mr. Poole was instrumental in aggressively growing revenue, building solid management teams and dramatically improving profitability. As President of these firms, Mr. Poole had total P&L responsibility and directly managed vice presidents in charge of each business department within the organizations. In recent years, Mr. Poole has acted as a private consultant and, until his appointment to the board, Mr. Poole served as a member of the Commercial Advisory Board of subsidiary, Arius Pharmaceuticals. Mr. Poole was Acting President/CEO of Spherics, Inc., a biotechnology company focusing on unique delivery mechanisms of certain drugs for the treatment of CNS diseases during 2007 and 2008. Mr. Poole is also a member of the board of directors of Accentia. Mr. Poole earned a B.A. in Psychology at Boston University.
Samuel Sears	Mr. Samuel P. Sears, Jr., is Independent Director of BioDelivery Sciences International Inc. Mr. Sears has experience in the biopharmaceutical, nutraceutical and biotechnology industries. Since 2006, Mr. Sears has been a partner at the law firm of Cetrulo and Capone, PC, where he currently serves as managing partner, and from 2000 to 2006, he provided private consulting and legal advisory services to start-up and early stage development companies. Since 2000, Mr. Sears has served as Director, Chairman of the Audit Committee, Chairman of the Executive Committee, and Member of the Compensation Committee of Commonwealth Biotechnologies, Inc. (NASDAQ: CBTEQ), a research and development support services company. From 1998 to 2000, Mr. Sears served as Vice Chairman and treasurer of American Prescription Providers, Inc., a specialty pharmacy network offering prescriptions and nutraceuticals to patients with chronic diseases. From 1994 through May 1998, Mr. Sears was Chief Executive Officer and Chairman of Star Scientific, Inc. (NASDAQ: CIGX). From 1968 to 1993, Mr. Sears was in private law practice. Mr. Sears is a graduate of Harvard College and Boston College Law School.
John Shea	Mr. John J. Shea is Independent Director of BioDelivery Sciences International Inc. He is currently the head of his own firm J. Shea Inc. and has also been a Quality Systems Adviser with Quintiles, a private consulting firm. Mr. Shea has also served in the capacity of Director of Quality Assurance and was responsible for the implementation of quality assurance procedures in a number of public companies. From 1987-1989, he served as Director of Quality Assurance at NeoRx Corporation. Mr. Shea was also the Director of Corporate Quality Assurance at Hexcel Corporation from 1980-1987. Mr. Shea has also served as the quality assurance person for other companies including, Teledyne Relays, Ortho Diagnostics, Inc. and Bio Reagents & Diagnostics, Inc. He is a member of the (North Carolina) Dare County Airport Authority and Audit Committee. Mr. Shea earned a B.S. in Chemistry at Bethany College.
Brian Korb

Basic Compensation

Name	Fiscal Year Total
Francis O'Donnell	43,131
Mark Sirgo	786,103
James McNulty	499,035
Andrew Finn	495,124
William Stone	--
Thomas D'Alonzo	--
William Poole	--
Samuel Sears	--
John Shea	--
Brian Korb	--

As Of 30 Dec 2012

Options Compensation

Name	Options	Value
Francis O'Donnell	130,000	6,650
Mark Sirgo	109,735	24,577
James McNulty	232,398	400,420
Andrew Finn	63,076	0
William Stone	0	0
Thomas D'Alonzo	0	0
William Poole	0	0
Samuel Sears	0	0
John Shea	0	0
Brian Korb	0	0

Insider Trading

Name	Shares Traded	Price
O DONNELL FRANCIS E JR	100,000	$0.00
SIRGO MARK A	2,475	$4.05
FINN ANDREW L	300	$4.04
FINN ANDREW L	200	$4.02
FINN ANDREW L	2,400	$4.05
POOLE WILLIAM S	12,000	$4.00
SIRGO MARK A	2,500	$4.00
FINN ANDREW L	200	$4.03
SHEA JOHN J	6,195	$4.19
MCNULTY JAMES A	18,616	$3.83
MCNULTY JAMES A	18,616	$6.14
SHEA JOHN J	25,000	$6.04
SHEA JOHN J	1,643	$2.29
SHEA JOHN J	1,643	$6.00
SHEA JOHN J	25,000	$2.26
STONE WILLIAM B	7,536	$6.02
STONE WILLIAM B	7,536	$2.29
STONE WILLIAM B	21,044	$6.00
SHEA JOHN J	23,357	$6.00
SHEA JOHN J	7,124	$6.00
SHEA JOHN J	23,357	$2.29
SHEA JOHN J	7,124	$3.83
STONE WILLIAM B	21,044	$2.29
STONE WILLIAM B	1,700	$2.29
STONE WILLIAM B	1,700	$6.00

» Full list on Insider Trading

People: BioDelivery Sciences International Inc (BDSI.PH)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: